Based on the evidence gathered so far, adequately chosen female hormone substitution can be clearly advantageous in some cancers (e.g. endometrial cancer, haematologic malignancies or colorectal carcinoma) and harmful in hormone dependent others (e.g. breast cancer, meningioma or ER+/PR+ gastric cancer). Here, PGR is linked to breast cancer.